It has been known for some time that castration-resistant prostate cancer tissue contains levels of signalling androgens sufficient to activate the androgen receptor, but the source of these steroids is highly controversial. For the first time we have performed a comprehensive screen of the steroidogenic potential of human benign, hormone naïve and progressive hormonally treated prostate cancer tissue, and identified that reduction of androstenedione via canonical enzyme pathways is the predominant source of signalling androgens. Importantly, we found no evidence of significant contribution from the previously described 'backdoor' or '5α-dione' pathway to androgen synthesis, in contrast to a body of work based on cell lines and xenograft models. These results have important implications for our understanding of continued androgen synthesis in human disease, as well as the rational design of future therapies. 
Statement of Translational Relevance
It has been known for some time that castration-resistant prostate cancer tissue contains levels of signalling androgens sufficient to activate the androgen receptor, but the source of these steroids is highly controversial. For the first time we have performed a comprehensive screen of the steroidogenic potential of human benign, hormone naïve and progressive hormonally treated prostate cancer tissue, and identified that reduction of androstenedione via canonical enzyme pathways is the predominant source of signalling androgens. Importantly, we found no evidence of significant contribution from the previously described 'backdoor' or '5α-dione' pathway to androgen synthesis, in contrast to a body of work based on cell lines and xenograft models. These results have important implications for our understanding of continued androgen synthesis in human disease, as well as the rational design of future therapies.
Introduction
Evidence accumulated over the last decade clearly indicates that continued activation of Androgen Receptor (AR) mediated signalling is critical to the development and progression of castration-resistant prostate cancer. This is supported by evidence of receptor upregulation and nuclear localisation both in experimental systems and clinical samples, as well as the increased expression of AR regulated transcripts (notably KLK3/PSA) with disease progression, and confirmed by the recent clinical success of second line hormonal agents that continue to target AR signalling (1) (2) (3) (4) (5) (6) . It is also clear that despite the presence of castrate levels of testosterone in serum, sufficient concentrations of the two most potent AR ligands, testosterone (T) and/or dihydro-testosterone (DHT) are present in human castration-resistant prostate cancer tissue at levels sufficient to activate AR, with potent inhibitors of androgen synthesis producing dramatic clinical responses in this phase of the disease (4, 7) . The origin of these androgens in human disease is unknown and highly controversial.
Under normal physiological conditions, T, the most important circulating androgen is synthesised de novo from cholesterol by Leydig cells in the testes by two parallel pathways (recently reviewed by Chang and Sharifi(8) ). In a common first step, C27 cholesterol is converted to C21 pregnenolone by CYP11A1 mediated cleavage of a C6 side-chain on the inner membrane of mitochondria. In a series of reactions, pregnenolone is then converted to C17 androstenedione by 17α-hydroxylase/17,20-lyase (CYP17A1) and 3β-hydroxysteroid dehydrogenase/Δ5Δ4 isomerase (HSD3B), via the alternative intermediates DHEA or progesterone depending upon the sequence of enzyme action. Androstenedione is then reduced to T by 17β-hydroxysteroid dehydrogenase (HSD17B), which may be further reduced to DHT in specific target organs that express 5α-reductase (SRD5A1/2). The weak androgen DHEA, and its sulphated form DHEA-S, are also synthesised and released by the Author Manuscript Published OnlineFirst on ; DOI: 10.1158/1078-0432.CCR- adrenal cells in the zona reticularis, but must be converted to T and/or DHT in peripheral tissues.
Three competing, although not mutually exclusive mechanisms have been proposed to explain the presence of significant concentrations of T/DHT in castration-resistant prostate cancer. The most widely accepted view is that these potent androgens are derived from the intra-tumoural conversion of weaker adrenal androgens based on normal physiological pathways. The critical feature of this mechanism is that T is an essential element, either as an AR ligand in its own right or as an immediate precursor for DHT. Two alternative pathways to DHT that bypass T have been recently described: de novo steroidogenesis via the 'backdoor pathway', as well direct conversion of androstenedione to DHT via the '5α-dione pathway' (9, 10) . The more contentious is the de novo mechanism, which proposes that castration-resistant prostate cancer cells develop the ability to generate steroids directly from cholesterol, with synthesis of DHT in a 7-8 step reaction that bypasses the canonical androstenedione-T axis. This entails conversion of pregnenolone to androstanediol via androsterone, and then directly to DHT by a mix of both canonical (CYP17A, HSD17B) and backdoor (RDH5, SRD5A1) enzymes. In the more recently described '5α-dione' pathway, it is proposed that adrenally derived androstenedione is reduced to 5α-androstanedione by SRD5A1, and then converted directly to DHT by HSD17B (see Figure 1 ).
Although there is significant overlap in the enzymes involved in each pathway, accurate knowledge of the exact mechanism involved is important for the rational design of more targeted inhibitors, with the potential for increased potency and fewer side-effects than currently available drugs. Unfortunately direct evidence to support any of the proposed mechanisms is lacking, with most of the data being derived from human cell lines or xenograft models, which may not accurately reflect the changes that occur in clinical disease.
We were therefore interested in directly determining the ability of hormone-refractory 
Materials and Methods

Tissue incubation with androgen precursors
Following institutional review board approval, fresh prostate tissue was collected from patients with benign prostatic hyperplasia, hormone-naïve or hormone-refractory prostate cancer undergoing transurethral resection (TURP) or radical prostatectomy for clinical indications. Patients with hormone refractory disease had evidence of clinical progression with or without a rising PSA despite treatment with androgen deprivation therapy (Table1).
No patient was being treated with a 5α-reductase inhibitor (finasteride, dutasteride) at the time of surgery. Collected tissue was placed in PBS in a specimen jar on ice, weighed, and then gently teased apart with scalpel and forceps under sterile conditions. As transurethral resection results in significant surface charring, tissue samples for steroid assays were preferentially prepared from the centre of larger prostate chips. The resulting minced tissue aggregates were then divided into 7 approximately equal portions, reweighed, and 6 of the 7 samples cultured in 2 ml of phenol red free RPMI (Gibco) containing 5% charcoalstripped serum and 1% penicillin/streptomycin in a 24-well plate (Falcon). The remaining sample of fresh tissue was snap frozen for RNA analysis. To five of the six tissue-containing wells 1μl of a 20μg/μl stock of testosterone, cholesterol, progesterone, androstenedione or DHEA was added, while the final well contained no additive. To account for continued androgen production in the absence of exogenous precursors, steroid measurements in individual patients were standardized to this negative control. Remaining tumour tissue was fixed in formalin, paraffin-embedded and sections stained with H&E for pathological assessment
Hormone extraction
The hormone extraction was carried out on 2ml of the supernatant from the tissue incubation.
The samples were transferred into a 12 x 75mm glass disposable culture tube (Kimble Chase) and 1μl of a 20μg/μl stock of 16,16,17,d3-testosterone was added to each sample as an internal standard. Ethyl acetate (Sigma-Aldrich) was added to the sample at a ratio of 1:1, the tube was then capped and inverted twice, the lid removed and the sample allowed to settle for 
RNA tissue extraction
Total RNA was extracted from snap frozen TURP tissue using the miRNeasy mini kit lower red organic layer containing the proteins. The upper layer containing the RNA was transferred to a new 1.5ml Eppendorf tube and 525µl of 100% ethanol was mixed in thoroughly by pipette. The sample was then transferred to an RNeasy mini spin column and centrifuged at 13,000rpm for 15sec at RT before discarding the flowthrough and adding 700µl of buffer RWT and centrifuging for a further 15sec at 13,000rpm at RT, discarding the flowthrough. 500µl of buffer RPE was added to the spin column and centrifuged at 13,000rpm for 15sec at RT before discarding the flowthrough and washing the column a second time with 500µl of buffer RPE and centrifuging for 2min at 13,000rpm at RT to dry the membrane. The spin column was placed in a fresh collection tube and centrifuged at 13,000rpm for 1min to remove any residual buffer RPE. The spin column was then transferred into a labelled Eppendorf tube and 37µl of RNase free water added to elute the RNA before centrifuging at 13,000rpm for 1min at RT. The concentration and purity of RNA was then determined using the NanoDrop 3300, before running a sample on an RNA gel to check RNA quality.
Gene Expression Microarray
The HumanHT-12v4 BeadChip (BD-103-0204, Illumina) was utilized for gene expression microarray profiling. Briefly, 100ng of total RNA was used as input for cDNA library construction with the Illumina®TotalPrep™RNA Amplification kit (AMIL1791, Applied Biosystems) as per manufacturers instructions. Poly-A RNA was selected and reverse transcribed to single stranded cDNA, converted to double stranded DNA and purified. The DNA was then transcribed in vitro overnight in the presence of biotinylated UTP and CTP to produce biotin-labelled cRNA. This cRNA was hybridised to the BeadChip over 16 hours.
Following addition of streptavidin-Cy3, the BeadChip was read using an iScan System (Illumina) and raw intensities generated from laser-excited fluorescence. 
Bioinformatics processing
BeadChip array analysis was performed using the limma package as part of Bioconductor in R(13). Raw intensities were background corrected using negative control probes and quantile normalisation was performed using negative and positive control probes. If there were multiple probes mapping to a gene, only the probe showing the maximum average intensity was retained. Batch effects were corrected using ComBat (14) . Heatmaps were generated using the heatmap.2 package and all intensities were normalised by row (gene). Gene set enrichment analysis (GSEA) was performed using the mean-rank gene set test in limma. 
Results
Androstenedione is the Preferred Precursor for Intra-Prostatic Testosterone Production
To determine the efficiency whereby various precursors undergo intra-prostatic conversion to more potent androgens, we measured the concentrations of 15 different steroids in the conditioned media following incubation of fresh BPH, androgen-naïve or hormone refractory prostate cancer tissue for 96 hours with excess cholesterol, progesterone, androstenedione, DHEA and testosterone. We observed that only incubation with androstenedione led to the generation of significant concentrations of T productions across all tissue types, and appreciable quantities of DHT were identified only when T was the precursor (Figure 2 ).
Notably we did not identify any significant DHT (or T) production when prostate tissue was incubated with two precursors of the 'de novo' pathway, cholesterol and progesterone, nor did we detect any significant production of DHT from DHEA or directly from androstenedione by the '5α-dione' pathway ( Figure S1 ), despite evidence of both SRD5A (T  DHT) and 3αHSD (androstenedione  androsterone) activity in hormone-refractory prostate cancer tissue. Small quantities of androsterone were identifiable in media from both benign and castration-resistant prostate tissue when incubated with cholesterol, suggesting that de novo synthesis may occur at a low background level, although there was no significant upregulation with hormone-resistance. When analysed by tissue type, hormone refractory prostate cancer (HRPC) was more efficient at converting androstenedione to 
testosterone than both benign tissue and androgen-naïve prostate cancer (Figure 2 inset) , although there was no significant difference in the ability to reduce T to DHT. Interestingly, T was more efficiently converted to androstenedione rather than DHT in both benign and castration-resistant prostate tissue, mirroring the results observed when androstenedione was used as a precursor, indicating preferential upregulation of HSD17B activity in these tissues.
Consistent with previous reports, progesterone, DHEA, androstenedione and T lead to increases in cholesterol production, particularly in hormone resistant tumour tissue (16) .
HRPC is Associated with a Significant Enrichment of HSD17B Expression
The synthesis of T and DHT from precursor molecules in androgenic tissue under normal physiological conditions occurs via a well-established sequence of reversible reactions, although more recently a number of alternative pathways have been described that bypass this canonical pathway in castration-resistant prostate cancer. As androgen levels may be affected by both changes in synthetic and degradative enzyme expression, and given the number of possibly redundant pathways involved, to obtain an unbiased global estimate of the expression of potential genes of interest we analysed gene expression in the same benign, androgen-naïve and hormone refractory prostate cancer specimens using the Illumina HumanHT-12 microarray. As shown in Figure 3a , although the expression of a number of genes of interest was consistently higher in hormone refractory compared to androgennaïve prostate cancer samples (HSD17B4, 7 & 12), the magnitude of measurement difference was small and did not meet significance using the stringent false discovery cut-offs. This is not surprising, given the small number of cases within each group, variance in expression, as well as the potential redundancy of activity across a number of different isoenzymes. We therefore performed geneset enrichment analysis using a number of pre- activity at a q-value <0.1 ( Figure 3b ). This is consistent with the results of our culture experiments, as HSD17B isoenzymes are responsible for the reversible 17-keto reduction of androstenedione to T.
HRPC is Associated with Overexpression of the Canonical Isoenzyme AKR1C3
To confirm some of the findings identified using the expression microarray, we performed quantitative PCR using RNA isolated from a subset of the same tissue samples, with at least 3 biological replicates in each group. Given the limited amount of starting RNA available from the sample set, we focussed on a small number of genes of interest, including the 'backdoor' genes CYP11A1, HSD17B9 (RDH5) and SRD5A1, as well as the canonical 17β-hydroxysteroid dehydrogenase HSD17B5 (AKR1C3) and the alternative isoform HSD17B4, which appeared to be consistently upregulated compared to naïve tissue, and overexpression of which has previously been associated with poor outcome in prostate cancer (17) . We found that the expression of AKR1C3 was significantly elevated in HRPC samples compared to both benign and androgen-naïve samples, whereas RHD5, was actually significantly decreased in CRPC samples compared to benign tissue (Figure 4) . Interestingly, consistent with previous reports, the expression of SRD5A1 was upregulated in hormone refractory tumours (18) , whereas SRD5A2 levels were unchanged.
AKR1C3 is Overexpressed in Hormone Refractory Metastases
It is clear that like many solid tumours, prostate cancers are molecularly heterogeneous, and it is possible that different mechanisms are preferentially active in tissue from alterative clinical sites. Due to the limited tissue availability from biopsy of metastases, for our steroidogenesis and expression assays we used tumour derived from transurethral resection or obtained at prostatectomy, which clearly represents events occurring in localised disease. To determine if 
Discussion
Ever since concentrations of potent signalling androgens sufficient to activate the AR under experimental conditions were measured in castration-resistant prostate cancer tissue, there has been much speculation as to their source. The orthodox view is that they are generated by the intra-tumoural conversion of adrenal precursors utilising physiological androgenic enzymes and reactions, culminating in the reduction of T to DHT. Recently two alternative reaction pathways that bypass T as the immediate precursor of DHT ('de novo' and 5α-dione pathway) have been proposed to be important in human disease. In this study, which is the first to comprehensively address androgen production by human prostate tissue at distinct stages of disease progression, we have identified that the only significant source of androgen precursor in any tissue type is the intermediate steroid androstenedione, and that the predominant potent androgen generated is T. Conversion of androstenedione to T was observed in both benign and malignant prostate tissue, suggesting that this is a normal physiological pathway, although the generation of T was significantly more efficient in hormone-resistant compared to hormone-naïve tumour. In particular, we did not identify any evidence of DHT production from the 'de novo' precursors cholesterol or progesterone, nor did we observe direct conversion of androstenedione to DHT via the 5α-dione pathway, despite evidence within the assay of necessary enzyme activity.
Consistent with the results of our steroid assay, we observed upregulation of HSD17B genes which are responsible for the reduction of androstenedione to T in castration-resistant prostate cancer samples on GSEA, and confirmed over-expression of the canonical substratespecific 17β-hydroxysteroid dehydrogenase isoenzyme AKR1C3 by PCR. A similar finding was observed specifically in castration-resistant metastases in the Taylor dataset, strongly suggesting that this mechanism is not limited to localised tissue. AKR1C3 expression has been previously shown to be hormonally regulated, in that treatment of cell lines with the synthetic androgen R1881suppressed transcript levels, whereas castration leads to its upregulation in xenograft models (20) . In addition, AKR1C3 expression is consistently intact male prostate with little detectable levels of SRD5A1 observed (26) . Genetic studies of mutant individuals have also confirmed the physiological role of SRD5A2 with individuals with 5a-reductase deficiency where pseudohermaphroditism and hypogonadism are exclusively mutants in the SRD5A2 gene but not in SRD5A1 (27) . This suggests that the key regulator of T to DHT conversion in prostate tumour tissues is in fact SRD5A2, which consistently declines in castrate resistant tissue due in part to lack of the well-known DHT feed forward regulatory effect (28, 29) . This would explain the relative accumulation of T over DHT in castrate resistant tissues, with SRD5A1 despite its relative increase in expression being unable to efficiently catalyze conversion of T to DHT in prostatic tissues despite evidence of its ability to do so in cell lines (10) . Supporting this is the observation that DHT was generated from precursor T across tissue types at a relative efficiency commensurate with SRD5A2, but not SRD5A1 expression. It is important to note however that we did not include metastatic tissue in our functional assays, and that much of the pre-clinical evidence supporting both the 'backdoor' and 5α-dione pathways has been generated using cell lines derived from clinical metastases. Therefore although the expression of genes involved in androgen synthesis in castration-resistant metastases is consistent with our observations in primary tumours, it remains possible that alternative pathways play a more prominent role in secondary sites of disease.
We note that appreciable concentrations of DHT were identified only when T was used a direct precursor, however in hormone resistant tumour tissue oxidation back to androstenedione was more efficient than reduction to DHT, suggesting that production of DHT in castrate resistant tissues is an inefficient process. It has been recognised for some disease progression or whether it is merely a consequence of it. Two large prostate cancer prevention trials have which have sought to manipulate the T to DHT ratios in the prostates of subjects potentially suggest that there may be functional consequences of switching these ratios within the prostate. The Prostate Cancer Prevention Trial showed that finasteride, a selective SRD5A2 inhibitor reduced the risk of prostate cancer by 25%, but among the tumours that were detected, there was a 27% increase in the number of those that had higher Gleason scores of 7 to 10(30). Similarly, the REDUCE trial examined the incidence of prostate cancer detected on biopsy among men at increased risk for the disease treated with dutasteride which unlike finasteride, inhibits both isoforms of 5α-reductase (31) . During years 3 and 4 of this trial there was a significantly increased number (P=0.003) of Gleason 8 to 10 tumours detected in the dutasteride group versus placebo (32) . There are many competing explanations for the increased risk of higher grade tumours detected in both these 5α-reductase inhibitor trials, however it remains plausible that the observed increases in high grade disease are at least in part due to the relative accumulation of T over DHT, a state commensurate with the prostatic milieu associated with advanced castrate resistant disease.
Collectively our results add further credence to calls for a comprehensive orchestrated targeting of the AR axis at the initiation of endocrine therapy rather than the sequential phasing in of such treatments as is commonly the practice today. Particularly pertinent to our results is the development of specific AKR1C3 inhibitors which would be interesting adjunct treatments that might specifically interfere with the switch in T to DHT ratios in the prostate (33) (34) (35) (36) (37) . represented by single dot points. Differences between groups were determined using independent 2-sided t-tests.
